Adventrx initiates pivital Phase 3 study of ANX-188

theflyonthewall.com

Adventrx Pharmaceuticals announced that it has initiated patient recruitment in its pivotal phase 3 clinical study of ANX-188 in sickle cell disease.

Rates

View Comments (1)